The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; GlaxoSmithKline; Halozyme; Histosonics; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics; Rafael Pharmaceuticals
Research Funding - Actuate Therapeutics (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen
 
David Bing Zhen
Consulting or Advisory Role - QED Therapeutics
Research Funding - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Seagen
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); tempes (Inst)
 
Shaalan Shaalan Beg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Cancer Commons; Foundation Medicine; Ipsen; Legend Biotech
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Tolero Pharmaceuticals (Inst)
 
Thomas Enzler
No Relationships to Disclose
 
Kent A. Griffith
No Relationships to Disclose
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Seagen